Aprea Therapeutics (APRE) Retained Earnings (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Retained Earnings of $389.6 million for Q1 2026, up 10.96% year-over-year from $351.1 million in Q1 2025, and up 3763.77% quarter-over-quarter from -$10.6 million in Q4 2025.
Aprea Therapeutics (APRE) Retained Earnings (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Retained Earnings for 9 consecutive years, with $389.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 10.96% year-over-year to $389.6 million; the TTM figure through Mar 2026 stood at $389.6 million (up 10.96% YoY), while the FY2025 annual figure was -$10.6 million, up 96.69% from the prior year.
- Retained Earnings grew to $389.6 million in Q1 2026 per APRE's latest filing, from -$10.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $389.6 million in Q1 2026 and bottomed at -$331.2 million in Q3 2025.
- Historically, Retained Earnings has averaged $13.2 million across 5 years, with a median of -$10.6 million in 2025.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 3396.19% — and 2025, when it tumbled 3023.0%.
- Aprea Therapeutics' Retained Earnings stood at $330.1 million in 2022, then sank by 193.34% to -$308.1 million in 2023, then declined by 4.21% to -$321.0 million in 2024, then soared by 96.69% to -$10.6 million in 2025, then jumped by 3763.77% to $389.6 million in 2026.
- Business Quant data shows APRE's Retained Earnings at $389.6 million in Q1 2026, -$10.6 million in Q4 2025, and -$331.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 389.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 389.60 Mn |
| Mar 31, 2026 | 389.63 Mn |
| Dec 31, 2025 | -10.63 Mn |
| Sep 30, 2025 | -331.19 Mn |
| Jun 30, 2025 | 352.25 Mn |
| Mar 31, 2025 | 351.15 Mn |
| Dec 31, 2024 | -321.04 Mn |
| Sep 30, 2024 | -10.60 Mn |
| Jun 30, 2024 | 350.55 Mn |
| Mar 31, 2024 | -310.89 Mn |
| Dec 31, 2023 | -308.08 Mn |
| Sep 30, 2023 | -10.64 Mn |
| Jun 30, 2023 | -10.63 Mn |
| Mar 31, 2023 | -298.18 Mn |
| Dec 31, 2022 | 330.06 Mn |
| Sep 30, 2022 | -10.24 Mn |
| Jun 30, 2022 | 261.80 Mn |
| Mar 31, 2022 | -189.07 Mn |
| Dec 31, 2021 | -10.36 Mn |
| Sep 30, 2021 | 237.23 Mn |